

A FUNDED CLINICAL TRIAL TO EVALUATE AN AUTOLOGOUS VACCINE PLUS ADOPTIVE T-CELL TRANSFER IN THE TREATMENT OF DOGS WITH OSTEOSARCOMA

Trial Specifics:

ACI is conducting a clinical trial in dogs with osteosarcoma, sponsored by Elias Animal Health, LLC. ELIAS Cancer Immunotherapy (ECI™) is a personalized T cell-based treatment that triggers the patient's immune system to eliminate cancer.

This trial is designed to evaluate the safety and efficacy of surgery combined with ECI-OSA-1 as a treatment for newly-diagnosed appendicular osteosarcoma. Following amputation, enrolled dogs will receive a series of vaccinations that are customized from the cancer tissue. Vaccines are once weekly for 3 weeks. After the vaccinations, the personalized T cells are collected through apheresis and then activated before being reinfused into the patient. Following intravenous infusion of activated T cells, enrolled dogs will be followed for up to 11 months. The follow-up visits will include bloodwork and thoracic radiographs every 3 months.

Trial Funding:

The owner will be responsible for the initial amputation surgery, and the remainder of the trial is fully funded for the full trial duration (11 months), including all visit procedures and treatments.

Trial Eligibility:

Dogs with osteosarcoma may be enrolled if they meet the specific criteria:

- Biopsy confirmation of appendicular osteosarcoma
- No prior or current anti-cancer treatment other than surgery for osteosarcoma
- No concurrent glucocorticoids or other immunosuppressive chemical agents
- No second malignancy or other uncontrolled medical condition that may be disruptive to the objectives of the study

The clinical trial is being offered at the following locations:

<p>The Oncology Service The LifeCentre West 134 Fort Evans Rd NE Leesburg, VA 20176 571-209-1176</p>	<p>The Oncology Service Dogwood Veterinary Specialty and Emergency Center 5918 West Broad St Richmond, VA 23230 804-716-4710</p>
---	---